In order to exploit differences in gene expression between when MUC1-positive cells were transduced with retronormal and malignant cells for genetic prodrug-activation viruses containing chimeric MUC1/ERBB2 promoters. No therapy, we have generated recombinant retroviruses consignificant sensitization to GCV was observed when taining the herpes simplex virus thymidine kinase coding MUC1-negative cells were transduced with these recombiregion cloned downstream of sequences derived from the nant retroviruses. These results suggest that one may be 5Ј-flanking regions of the MUC1 and ERBB2 genes. Transable to develop a tumour-selective therapy by utilizing the duction with retroviruses containing MUC1 promoters transcriptional regulatory regions of the MUC1 and ERBB2 resulted in an increase in GCV sensitivity in MUC1-positive genes to drive the expression of suicide genes. cells. A further increase in GCV sensitivity was achieved Keywords: suicide gene; tumour-selective expression; retroviral vectors; MUC1 promoter; ERBB2; HER2/neu GPAT system, now in clinical trial, using the ERBB2 proIntroduction moter to drive expression of prodrug activating enzyme Genetic prodrug activation therapy (GPAT) is one of the genes. 6 Bosher et al 7, 8 recently demonstrated that the APmost promising approaches to the gene therapy of cancer 2 family of transcription factors is involved in the reguand following successes in a variety of animal models lation of ERBB2 expression in mammary carcinoma. there are now several clinical trials in progress. 1, 2 In order Indeed, expression of at least one member of the AP-2 to be effective, the therapy has to be targeted specifically family was shown to be up-regulated in all of the ERBB2-to tumour cells while leaving normal cells unaffected, overexpressing breast tumour cell lines tested. It may be which has been achieved by two general strategies: tarpossible to exploit this observation in order to enhance geted delivery and targeted expression.
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the activity of suicide gene constructs and thus the effiTargeted delivery can be achieved relatively simply cacy of a gene therapy strategy. using retroviruses for targets such as intracranial As more information is accumulated about the molecutumours, where only the neoplastic cells are proliferating lar profile of a particular tumour type it may also be posand hence susceptible to retrovirus infection. 3 Targeted sible to design more sophisticated systems that combine delivery may also be possible for particular somatic cell expression regulatory elements from two or more genes types by engineering specific ligands into retroviral to achieve more precise modulation of suicide gene envelopes or adenoviral capsids, as well as the use of expression within tightly restricted target cell popumolecular conjugates incorporating antibodies or other lations. As a first step towards achieving this end, we molecules.
have explored the utility of elements in the promoter of Targeted expression exploits the transcriptional reguthe MUC1 gene, alone and in combination with tumourlatory elements (promoters and enhancers) of genes that selective enhancer elements. The MUC1 gene encodes the are expressed in a tissue-specific or tumour-specific manpolymorphic epithelial mucin (PEM) which is expressed ner. Examples of tissue-directed targeting include the use in epithelial cells lining the glands or ducts of the stomof the tyrosinase gene promoter to drive expression in ach, pancreas, lungs, trachea, kidney, uterus, salivary melanocytes and related neoplasms, 4 as well as the proglands and mammary glands. 9, 10 The level of PEM moter of the carcinoembryonic antigen (CEA) gene which expression is increased in most carcinomas and although is expressed in tumours derived from the gastrointestinal there is evidence for amplification of the MUC1 locus at tract. 5 We have previously exploited the observation that 1q21-q24 in some cases of breast cancer 11 the usual mechbreast and pancreatic cancers frequently overexpress the anism appears to be transcriptional up-regulation.
A number of studies have been carried out in order to identify the regulatory sequences responsible for the tissue-specific expression of MUC1. In one study, deletion analysis of MUC1 regulatory sequences has shown that maximal expression of reporter genes is obtained in the MUC1-expressing ZR75.1 and HPAF cell lines with only 743 bp of 5Ј-flanking sequence. 15 Furthermore, sequences between −858 and −401 relative to the transcription initiation site were shown to be able to enhance the activity of the basal SV40 promoter in a tissue-specific manner. In another study, Abe and Kufe 16 localized enhancing sequences to between positions −598 and −485. This region contains three potential SP1-binding sites and an AP-2-like motif. The proximal 5Ј-sequences (−150/+33), although lacking transcriptional activity in isolation, exhibited cell type-specific promoter activity when influenced by the SV40 enhancer element. Therefore, tissue-specific expression of MUC1 appears to be regulated both by promoter sequences in the proximal 5Ј-region of the gene and more distal enhancer elements.
In an attempt to develop novel cancer treatments based upon the selective expression of suicide genes in tumour cells, we constructed a number of retroviral constructs containing the herpes simplex type 1 thymidine kinase gene (HSVtk) linked to sequences that have previously been shown to be important in the tissue-specific expression of MUC1 and ERBB2.
Results

Figure 1 Schematic representation of the recombinant retroviral vectors
In order to determine if 5Ј-flanking sequences of the DCAPMPtk construct is associated with a significant were used to infect two MUC1-positive cell lines (IMIMincrease in GCV sensitivity over the results obtained with PC2 and T47D) and two MUC1-negative cell lines (T3M4 the DCMtk construct. In contrast, however, transduction and MTSV 1.7). The MUC1 expression status of the cell of T47D cells with DCMEEPtk does not result in an lines was determined by Northern analysis (see Figure 2) . increase in GCV sensitivity over that observed with The sensitivity of the stably transduced cell lines to GCV DCMtk (see Figure 5 ). Transduction of IMIM-PC2 cells was determined by a modified MTT assay (Promega). It with either the DCMEEPtk or the DCAPMPtk constructs can be seen from Figure 3 that infection with the DCMtk resulted in a significant increase in GCV sensitivity relavector significantly enhanced the GCV sensitivity of tive to DCLMtk-transduced IMIM-PC2 cells. Transduc-T47D cells but not IMIM-PC2 cells, whereas the DCLMtk tion of the MUC1-negative MTSV 1.7 or T3M4 cell lines vector was able to enhance the GCV sensitivity of IMIMwith either the DCMEEPtk or DCAPMPtk vectors did not PC2 cells but not T47D cells. No significant increase in result in an increase in GCV sensitivity when compared GCV sensitivity occurred in the MUC1-negative T3M4 to the parental line (see Figure 5 ). Northern blot analysis and MTSV1.7 cell lines ( Figure 3) .
showed that the pattern of HSVtk mRNA expression was In an attempt to enhance further the sensitivity of cells generally consistent with the sensitivity of each transto the action of GCV, two more retroviral vectors were duced cell line on exposure to the prodrug ganciclovir constructed (designated DCMEEPtk and DCAPMPtk) ( Figure 6 ), except for the anomalous result that containing chimeric promoters derived from sequences expression of HSVtk was detectable in IMIM-PC2 DCMtk within the 5Ј-flanking regions of the MUC1 and ERBB2 cells but not in IMIM-PC2 DCLMtk cells. genes. Vector DCMEEPtk contains a fusion of the distal MUC1 enhancer sequences (−598/−485) to a fragment of the ERBB2 promoter (−500/+40). Vector DCAPMPtk conDiscussion tains a chimeric promoter consisting of an oligonucleotide containing three AP-2 binding sites linked to the This study has shown evidence that transcriptional regulatory elements from the human MUC1 gene could be proximal promoter sequences (−228/+33) of the MUC1 gene that have been demonstrated to drive tissue-specific exploited for genetic prodrug activation therapy of breast and pancreatic cancer. Only tumour cells which express expression when fused to the SV40 enhancer (see Figure 1 ). The AP-2 expression status of the cell lines was MUC1 transcripts are made sensitive to the cytotoxic effects of exposure to therapeutic concentrations of determined by immunoblotting (see Figure 4) . It can be review of these data suggest that other features are involved in controlling expression because there is poor correlation between the endogenous level of MUC1 expression and the activity of the reporter constructs. Abe and Kufe 16 identified an enhancer element situated at −598 to −485 in the 5Ј-flanking sequence which can drive expression through a heterologous minimal promoter in a selective manner in breast cancer cells following retroviral infection. 18 More recently Shirotani et al 19 have reported that the region at position −531 to −520 represents a 'responsive mucin element' which can mediate induction of expression after exposure of colon carcinoma cells to a soluble stimulatory factor derived from colon-conditioned medium. Hollingsworth et al 20 identified a series of purine/pyrimidine mirror repeat elements (PMR) in the MUC1 promoter, one of which (at −133 to −102) has a sequence nearly identical to a PMR in the human CFTR gene. This is an intriguing observation in view of the similar (but not identical) patterns of expression of these two genes in simple epithelial cells in adult and developing tissues, but the mechanism by which PMRs operate and their significance in controlling tissue-specific expression of MUC1 remains obscure. There has been a suggestion that DNA methylation at some regions of the MUC1 gene may influence its expression 21 although the mechanism is unclear since the methylation appears to affect only the repeat region within the coding sequence rather than the promoter moter in the DCMtk construct used in our experiments) to construct a genetic prodrug activation system with the HSVtk gene in an adenoviral vector which they applied ganciclovir, while cells which do not express MUC1 remain unaffected. Interestingly, the elements within the to a breast cancer model (MCF-7 cell line). They found that transduction of breast cancer cells produces MUC1 promoter/enhancer fragment which drive selective expression appear to be distinct in the tumour cells status-dependent sensitization to the toxic effects of ganciclovir in vitro, and administration of the adenovirus derived from the breast (T47D) or pancreas (IMIM-PC2), respectively. Transduction of the T47D cell line with the directly to peritoneal tumour deposits resulted in inhibition of tumour growth upon ganciclovir treatment. Our retroviral vector bearing the −743/+33 MUC1 promoter fragment (DCMtk) resulted in a significant increase in results show that this promoter fragment (DCMtk) produces effective expression in another breast cancer cell GCV sensitivity, whereas the vector containing the −1406/+33 MUC1 promoter fragment (DCLMtk) did not.
line (T47D), but not in a MUC1-positive pancreatic cell line (IMIM-PC2). The difference in the promoter fragIn the case of the IMIM-PC2 cell line, however, the reverse was observed; transduction with DCLMtk ments required to produce expression of the HSVtk gene in the MUC1-positive breast and pancreatic cancer cell resulted in a GCV sensitivity increase, whereas DCMtk did not. The reason for this difference is uncertain. It is lines in our experiments is an important observation and will need to be carefully considered in the design of gene clear that sequences upstream of −743 are required for the expression of HSVtk in IMIM-PC2 cells. The lack of therapy systems for clinical application in different tumour types. an effect on GCV sensitivity upon transduction of T47D cells with the DCLMtk vector could be explained by the The dramatic increase in the GCV sensitivity of T47D cells transduced with the DCAPMPtk vectors over the binding of negative factors to sequences upstream of −743 in these cells.
parental line, and indeed T47D cells transduced with the DCMtk vector, is probably because these cells express the The human MUC1 gene has been investigated intensively to identify the regulatory sequences responsible for AP-2 transcription factor (see Figure 2 ) which is therefore acting on the AP-2 binding sites in the construct and its tissue-specific expression. Peat et al 17 used a 10.6 kb fragment of genomic DNA containing 1.6 kb of 5Ј-and enhancing the activity of the MUC1 minimal promoter sequence. This illustrates the potential for exploiting 2.3 kb of 3Ј-flanking sequence to produce transgenic mice which showed the predicted pattern of expression in detailed knowledge of the molecular profile of tumour cells for therapeutic benefit and shows that heterologous adult tissues as well as appropriate developmental regulation. Detailed analysis of deletion mutants of the 5Ј-promoter and enhancer elements may be combined to select targets on the basis of both tissue-specific and flanking region in transient transfection assays indicated that the sequences between −60 and −150 were partitumour-specific gene expression. However, the results also demonstrate that selection may not be straightforcularly important for selective expression in breast (ZR75.1) and pancreatic (HPAF) cancer cell lines, 15 but ward because the operation of transcriptional control
Figure 3 Effect of recombinant retroviruses containing MUC1 promoters on the GCV sensitivity of target cells. MUC1-positive cell lines (T47D, IMIM-PC2) and MUC1-negative cell lines (T3M4, MTSV 1.7) were infected with the recombinant retroviruses DCMtk or DCLMtk. Transduced cells were selected in G418-containing growth medium. Clones were pooled, expanded and then incubated with GCV for 7 days. The proportion of surviving cells was assessed using a modified MTT assay as described in Materials and methods. Error bars denote standard error from the mean of quadruplicate samples.
candidates since they are frequently up-regulated during tumorigenesis.
27,28
Materials and methods Dr MA Hollingsworth, Eppley Institute for Cancer Research, Durham, NC, USA), for HSVtk using an ␣-32 Plabelled 0.416 kb fragment digested from pERBB2TK with PstI and HindIII. Following hybridization, the membrane elements can be context-dependent. Since T47D cells are was washed and subjected to autoradiography (Fuji RX ERBB2-negative, the −500/+40 ERBB2 promoter fragment film; GRI, Dunmow UK) at −70°C for 3-5 days. The memwould also be expected to be inactive. However, the branes were then stripped and hybridised with cDNA increase in GCV sensitivity induced upon transduction probes for either glyceraldehyde-3-phosphate dehydroof T47D cells with DCMEEPtk suggests that MUC1-genase (GAPDH) or ␤-actin mRNAs which are ubiquienhancer sequences are capable of activating an othertously expressed and therefore act as controls for filter wise silent ERBB2 promoter, leading to HSVtk loading. expression.
The dramatic increase in the GCV sensitivity of IMIMImmunoblot analysis to determine AP-2 expression PC2 cells following transduction with DCMEEPtk is status expected since this cell line expresses both MUC1 (see Crude nuclear extracts were prepared as described by Figure 1 ) and ERBB2 (data not shown). However, the Dignam et al, 29 separated by SDS/PAGE and transferred increase in the sensitivity of this line following transducto nitrocellulose. The blot was incubated with a mix of tion with DCAPMPtk is more surprising since IMIM-PC2 antisera capable of detecting all three AP-2 proteins. 8 cells do not express AP-2 ( Figure 2 ). It is possible that a Binding of primary antibodies was visualised using the factor present in IMIM-PC2 cells binds either to a ECL system (Amersham). sequence within the oligonucleotide used to create the chimeric promoter (other than the AP-2 sites) or to a site Construction of MUC1 enhancer/promoter-HSVtk created during the construction of the vector, leading to expression cassettes the activation of the otherwise silent MUC1 promoter.
What is clear from the results presented here is that pNLMtk and pNMtk: A plasmid consisting of the transduction of the MUC1-negative T3M4 and MTSV1.7 −1406/+33 MUC1 5Ј-flanking sequence cloned into the cell lines with any of the retroviral vectors used in this EcoRV site of pBluescript SK+ was kindly provided by study did not result in an increase in GCV sensitivity.
Dr J Taylor-Papadimitriou (ICRF, London, UK). The This is an important factor when considering the clinical −1406/+33 MUC1 5Ј-flanking sequence was excised with application of these constructs, since to reduce the possiSalI and cloned into the SalI site of pHStk−, containing bility of toxicity it will be as important to prevent the HSVtk coding sequence (provided by JD Harris, expression in essential host tissue as to enhance ICRF, London) in order to create pLMtk. The fragment expression in the target tumour. The principle of combincontaining the −1406/+33 MUC1 sequence and the HSVtk ing heterologous promoter elements could be extended coding sequence was excised by digestion with XhoI and to other targeted gene therapies and will be particularly XbaI, treated with dNTPs and Klenow polymerase to genuseful for genetic prodrug activation therapy. There are erate flush ends and cloned into the SnaBI site of N2A 30 already a number of tissue-selective promoters which to create pNLMtk. A fragment of pLMtk containing have been proposed for targeting tumours with a parti-−743/+33 MUC1 sequence and the HSVtk coding cular differentiation, such as the CEA gene promoter for sequence was excised by digestion with BstEII and colorectal, lung and pancreatic cancers [23] [24] [25] and the tyroXbaI, blunt-ended and cloned into SnaBI site of N2A to sinase gene promoter for melanoma. 4, 26 However, these create pNMtk. genes are expressed as part of the differentiation programme of the normal tissues from which these tumour types arise and there is a need to restrict the expression pNMEEPtk: The 5Ј-flanking sequence of the MUC1 gene representing positions −598/−485 (the MUC1 'enhancer' of the GPAT system to the transformed cell population selectively. We suggest that it should be possible to was amplified by PCR using primers SEMUC (5ЈCAAGCTTGCTGGAAAGTCCGGGCTGGG3Ј) and exploit our knowledge of the molecular profile of such tumours in order to select appropriate transcriptional ASEMUC (5ЈGATATCTAGTTTTGGGCTCCCTCCC3Ј) and cloned into the EcoRV site of pBluescript SK+ regulatory elements to combine with the tissue-selective promoters, and that genes encoding growth factors and (Stratagene, Cambridge, UK). A SmaI fragment containing the ERBB2 promoter sequence (−500/+40) was ligated their receptors such as ERBB2 may be particularly good Becton Dickinson, Oxford, UK) with a range of concentrations of ganciclovir (Cymevene, Syntex Pharmaceuticals, Maidenhead, UK). Samples were tested in quadinto the SmaI site of the resulting plasmid. A fragment ruplicate (error bars represent standard errors of the containing the MUC1 'enhancer' and the ERBB2 promoter mean). Cell death was assessed using a modified MTT was excised from the plasmid by digestion with HindIII, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium brotreated with dNTPs and Klenow polymerase to generate mide) assay (Promega, Southampton, UK). Formazan flush ends and cloned into the HincII site of pHStk−. The products were detected using an automated plate reader cassette containing the MUC1 'enhancer', ERBB2 pro-(HelisBio, Newmarket, UK). Results are expressed as a moter and the HSVtk coding sequence was excised by percentage of infected, drug-free controls. digestion with XhoI and XbaI, blunt-ended by treatment with dNTPs and Klenow polymerase and cloned into the
